These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12948437)

  • 21. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium antagonists: effects on cardio-renal risk in hypertensive patients.
    Nathan S; Pepine CJ; Bakris GL
    Hypertension; 2005 Oct; 46(4):637-42. PubMed ID: 16172420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating hypertension in the diabetic patient: therapeutic goals and the role of calcium channel blockers.
    Caldwell BV
    Clin Ther; 1993; 15(4):618-36; discussion 617. PubMed ID: 8221813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy of calcium channel blocker in hypertensive patients with chronic kidney disease].
    Morihira M; Kikuchi K; Nakagawa N; Fujino T; Hasebe N
    Nihon Jinzo Gakkai Shi; 2009; 51(4):451-5. PubMed ID: 19601552
    [No Abstract]   [Full Text] [Related]  

  • 25. L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
    Hayashi K
    Hypertens Res; 2011 Aug; 34(8):910-2. PubMed ID: 21753772
    [No Abstract]   [Full Text] [Related]  

  • 26. Calcium channels blockers and progression of kidney disease.
    Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
    Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapy for hypertension associated with kidney disease].
    Suzuki H
    Nihon Naika Gakkai Zasshi; 2003 Feb; 92(2):264-9. PubMed ID: 12652731
    [No Abstract]   [Full Text] [Related]  

  • 29. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease.
    Andersen NH; Mogensen CE
    Curr Hypertens Rep; 2004 Oct; 6(5):369-76. PubMed ID: 15341690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes and hypertension: how low should you go and with which drugs?
    Weir MR
    Am J Hypertens; 2001 May; 14(5 Pt 2):17S-26S. PubMed ID: 11370956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protecting the residual renal function: how do ACE inhibitors and calcium antagonists compare?
    Maschio G
    Nephron; 1994; 67(3):257-62. PubMed ID: 7936013
    [No Abstract]   [Full Text] [Related]  

  • 33. Calcium antagonists and renal disease.
    Epstein M
    Kidney Int; 1998 Nov; 54(5):1771-84. PubMed ID: 9844161
    [No Abstract]   [Full Text] [Related]  

  • 34. [Novel actions of calcium channel blockers].
    Kumagai H; Onami T; Takimoto C; Iigaya K; Hayashi K
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():311-7. PubMed ID: 16983770
    [No Abstract]   [Full Text] [Related]  

  • 35. Calcium antagonists and the kidney.
    Epstein M
    J Cardiovasc Pharmacol; 1994; 24 Suppl A():S18-24. PubMed ID: 7603073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
    Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The renal effects of calcium antagonists].
    Schulte KL; Lenz T
    Dtsch Med Wochenschr; 1993 Sep; 118(36):1293-300. PubMed ID: 8375300
    [No Abstract]   [Full Text] [Related]  

  • 38. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hypertension in chronic renal insufficiency.
    Locatelli F; Manzoni C; Marcelli D
    J Nephrol; 1997; 10(4):220-3. PubMed ID: 9377731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal protection with calcium antagonists: the role of lercanidipine.
    Burnier M
    Curr Med Res Opin; 2013 Dec; 29(12):1727-35. PubMed ID: 24069902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.